abstract
Recent results suggest that [3] ferrocenophane may be an interesting motif in the development of cytotoxic anti-cancer agents. We here report the synthesis of three such compounds based on the 1-[(p-R-phenyl)-phenyl-methylidenyl)]- [3] ferrocenophane skeleton with R = OH, NH2
and NHC(O)CH3 substitution on one of the phenyl rings. Cytotoxicity studies show that these compounds are up to four times more powerful against hormone-independent breast cancer cells than their corresponding ferrocene analogs. and 0.6 µM on hormone-independent MDA-MB-231 breast cancer cells. The point of attachment of the olefin was shown to be critical; when it was transposed from the 1 to the 2 position of the bridge, the cytotoxic properties declined by an order of magnitude. This could be a result of breaking the conjugation between the ferrocene group and the phenol groups, as it has been shown that conjugated molecules in this class are more toxic than their unconjugated analogs. 3 Ferrocene has been widely used in experimental medicinal chemistry, 4-6 including a [3] ferrocenophane created from the coordination of the 1,1'-bis(diphenylphosphino)ferrocene with gold, which was active against a panel of cancer cells. 7 We have also examined the influence of changing the hydroxyl group for other functionalities, such as amines and halogens. 8 The presence of a protic substituent is crucial for activity, and toxicity can be enhanced by replacement of the hydroxy group by NH2 or
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8 This is consistent with our proposed mechanism that quinoid compounds generated in situ are responsible for the toxicity of these compounds. 9 We here show that, in this system, the [3] ferrocenophane motif is more toxic than the ferrocene moiety, via the comparison of the ferrocene compounds 3a-c ( Our previous studies of non-cyclic tetra-substituted ferrocenyl olefins show that parasubstitution of one or more of the phenyl rings with OH, NH2, and NHC(O)CH3 yield the most toxic compounds. Thus we have tested the ferrocene and ferrocenophane derivatives with such substitution on the hormone-independent MDA-MB-231 breast cancer cell line, which does not respond to estrogenic or anti-estrogenic properties of molecules. Table 1 shows that IC50 values for the ferrocene-based compounds ranges from 1.1 to 0.65 µM. The ferrocenophane compounds are more toxic in each instance, with IC50 values ranging from 0.47 to 0.21 µM. Compounds 4c and 4a showed about a two-fold improvement, while 4b, with NH2 substitution, was significantly more potent than its non-cyclic analog.
It should also be noted that the presence of two phenol groups versus one enhances the toxicity of compounds in both the ferrocene and [3] ferrocenophane series. In the ferrocene series the IC50 decreased from 1.13 to 0.6 µM for the monophenol and diphenol;ferrocenophanes the corresponding decrease is from 0.47 to 0.09 µM. 1 Therefore, the next logical step is to prepare compounds with two identical or mixed substituents, particularly incorporating the NH2 group. With some nuances regarding the magnitude of the antiproliferative effect observed as a function of the substituents, NH2, OH, and NHC(O)CH3, it is clear that the rigid [3] ferrocenophane permits an increase in the cytotoxic efficacy of the Fc-alkene-phenyl-R motif.
Supplementary data
Crystallographic data (excluding structure factors) for the structure in this Intensity data (ϕ and scans) were collected with a Enraf-Nonius Kappa-CCD diffractometer equipped with a CCD two-dimensional detector. Data reduction was performed with DENZO/SCALEPACK. Data were corrected for Lorentz and polarization effects, and an semi-empirical absorption correction based on symmetry equivalent reflections was applied using SADABS. Lattice parameters were obtained from least-squares analysis of 100 reflections. The structures were solved by direct methods and refined by full matrix least squares, based on F 2 , using the Crystals software package. All nonhydrogen atoms were refined with anisotropic displacement parameters. All hydrogen atoms were located with geometrical restraints in riding mode. C26H23FeO; 407.32 g mol 
